Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07627074 · ClinicalTrials.gov registry record
Weight Loss in Adults Using Semaglutide (Real-world Study)
A clinical trial, sponsored by Novo Nordisk A/S.
- Recruiting
- Registry status
- 35,000
- Enrollment target
NCT07627074 is a clinical trial that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 35,000 participants.
The verdict
NCT07627074 is actively recruiting participants, sponsored by Novo Nordisk A/S.
- RECRUITING
- Registry status
- 35,000 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician.
Interventions
- DRUG Semaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35,000 participants |
| Start Date | 2026-05-12 |
| Est. Completion | 2026-06-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07627074
The ClinicalTrials.gov registry entry for NCT07627074 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 35,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Semaglutide is the first listed.
NCT07627074 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07627074 about?
NCT07627074 is a clinical study titled "Weight Loss in Adults Using Semaglutide (Real-world Study)". The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician.
What is the current status of trial NCT07627074?
This trial is currently recruiting. The enrollment target is 35,000 participants. The study started on 2026-05-12. Estimated completion is 2026-06-01.
What interventions are being tested in trial NCT07627074?
The interventions under investigation include: Semaglutide (DRUG).
Who is sponsoring clinical trial NCT07627074?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.